{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:46Z","timestamp":1792782526551,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AMED","award":["24ama221338h0001"],"award-info":[{"award-number":["24ama221338h0001"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"crossref"}]},{"name":"JSPS KAKENHI Grant","award":["22K09231"],"award-info":[{"award-number":["22K09231"]}]},{"DOI":"10.13039\/501100007533","name":"Kobayashi Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008643","name":"Japan Brain Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008643","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Osaka Community Foundation","id":[{"id":"https:\/\/ror.org\/03x5wxe68","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yasuda Kinen Medical Foundation","id":[{"id":"https:\/\/ror.org\/02zfaen51","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007263","name":"Astellas Foundation for Research on Metabolic Disorders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04475-z","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:35:59Z","timestamp":1783517759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intracranially injected chimeric antigen receptor T cells eradicate glioblastoma cells but have limited potential to persist in the brain in a syngeneic mouse model"],"prefix":"10.1007","volume":"75","author":[{"given":"Koki","family":"Murakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Tachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanji","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Hagioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Kishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"10","key":"4475_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"RMW Stupp","year":"2005","unstructured":"Stupp RMW, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996","journal-title":"N Engl J Med"},{"issue":"23","key":"4475_CR2","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"RTS Stupp","year":"2015","unstructured":"Stupp RTS, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314(23):2535\u20132543","journal-title":"JAMA"},{"key":"4475_CR3","doi-asserted-by":"crossref","unstructured":"O\u2019Rourke DM NM, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017; 9(399): eaaa0984.","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"4475_CR4","doi-asserted-by":"crossref","unstructured":"Majzner RG RS, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, Geraghty AC, Good Z, Mochizuki AY, Gillespie SM, Toland AMS, Mahdi J, Reschke A, Nie EH, Chau IJ, Rotiroti MC, Mount CW, Baggott C, Mavroukakis S, Egeler E, Moon J, Erickson C, Green S, Kunicki M, Fujimoto M, Ehlinger Z, Reynolds W, Kurra S, Warren KE, Prabhu S, Vogel H, Rasmussen L, Cornell TT, Partap S, Fisher PG, Campen CJ, Filbin MG, Grant G, Sahaf B, Davis KL, Feldman SA, Mackall CL, Monje M. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022 Mar;603(7903):934\u2013941. 2022; 603(7903): 934\u2013941.","DOI":"10.1038\/s41586-022-04489-4"},{"issue":"18","key":"4475_CR5","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","volume":"21","author":"CEBB Brown","year":"2015","unstructured":"Brown CEBB, Barish ME, Weng L, Ostberg JR, Chang WC, Naranjo A, Starr R, Wagner J, Wright C, Zhai Y, Bading JR, Ressler JA, Portnow J, D\u2019Apuzzo M, Forman SJ, Jensen MC (2015) Bioactivity and safety of IL13Ra2-redirected chimeric antigen receptor CD8\u00fe T cells in patients with recurrent glioblastoma. Clin Cancer Res 21(18):4062\u20134072","journal-title":"Clin Cancer Res"},{"issue":"14","key":"4475_CR6","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BDGE Choi","year":"2024","unstructured":"Choi BDGE, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, Maus MV (2024) Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med 390(14):1290\u20131298","journal-title":"N Engl J Med"},{"issue":"11","key":"4475_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.694941","volume":"21","author":"QBT Lin","year":"2021","unstructured":"Lin QBT, Ho J, Chen D, Cheng Y, Wang L, Xu G, Xu L, Zhou Y, Wei Y, Li J, Ling F (2021) First-in-human trial of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose. Front Oncol 21(11):694941","journal-title":"Front Oncol"},{"issue":"8","key":"4475_CR8","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"NBV Ahmed","year":"2017","unstructured":"Ahmed NBV, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S (2017) HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol 3(8):1094\u20131101","journal-title":"JAMA Oncol"},{"issue":"5","key":"4475_CR9","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJLM Bagley","year":"2024","unstructured":"Bagley SJLM, Fraietta JA, Wang X, Desai AS, Bagley LJ, Nabavizadeh A, Jarocha D, Martins R, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz R, Jadlowsky JK, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Sun Y, Gladney W, Barrett D, Nasrallah MP, Hwang WT, Ming GL, Song H, Siegel DL, June CH, Hexner EO, Binder ZA, O\u2019Rourke DM (2024) Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med 30(5):1320\u20131329","journal-title":"Nat Med"},{"issue":"15","key":"4475_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1342625","volume":"21","author":"MHJ Gutova","year":"2024","unstructured":"Gutova MHJ, Ma E, Natri HM, Adhikarla V, Chimge NO, Qiu R, Nguyen C, Melendez E, Aguilar B, Starr R, Yin H, Rockne RC, Ono M, Banovich NE, Yuan YC, Brown CE, Kahn M (2024) Targeting Wnt signaling for improved glioma immunotherapy. Front Immunol 21(15):1342625","journal-title":"Front Immunol"},{"issue":"26","key":"4475_CR11","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CEAD Brown","year":"2016","unstructured":"Brown CEAD, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D\u2019Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B (2016) Regression of glioblastoma after chimeric antigen receptor T-Cell therapy. N Engl J Med 375(26):2561\u20132569","journal-title":"N Engl J Med"},{"issue":"1","key":"4475_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41392-021-00505-7","volume":"6","author":"XWY Tang","year":"2021","unstructured":"Tang XWY, Huang J, Zhang Z, Liu F, Xu J, Guo G, Wang W, Tong A, Zhou L (2021) Administration of B7\u2013H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma. Signal Transduct Target Ther 6(1):125","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4475_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NAWA Vitanza","year":"2023","unstructured":"Vitanza NAWA, Huang W, Seidel K, Brown C, Gustafson JA, Yokoyama JK, Johnson AJ, Baxter BA, Koning RW, Reid AN, Meechan M, Biery MC, Myers C, Rawlings-Rhea SD, Albert CM, Browd SR, Hauptman JS, Lee A, Ojemann JG, Berens ME, Dun MD, Foster JB, Crotty EE, Leary SES, Cole BL, Perez FA, Wright JN, Orentas RJ, Chour T, Newell EW, Whiteaker JR, Zhao L, Paulovich AG, Pinto N, Gust J, Gardner RA, Jensen MC, Park JR (2023) Intraventricular B7\u2013H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov 13(1):114\u2013131","journal-title":"Cancer Discov"},{"issue":"4","key":"4475_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CEHJ Brown","year":"2024","unstructured":"Brown CEHJ, Alizadeh D, Blanchard MS, Natri HM, Wang D, Ostberg JR, Aguilar B, Wagner JR, Paul JA, Starr R, Wong RA, Chen W, Shulkin N, Aftabizadeh M, Filippov A, Chaudhry A, Ressler JA, Kilpatrick J, Myers-McNamara P, Chen M, Wang LD, Rockne RC, Georges J, Portnow J, Barish ME, D\u2019Apuzzo M, Banovich NE, Forman SJ, Badie B (2024) Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med 30(4):1001\u20131012","journal-title":"Nat Med"},{"issue":"4","key":"4475_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","volume":"42","author":"SLMR Goff","year":"2019","unstructured":"Goff SLMR, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA (2019) Pilot Trial of Adoptive transfer of chimeric antigen receptor-transduced T Cells targeting EGFRvIII in patients with glioblastoma. J Immunother 42(4):126\u2013135","journal-title":"J Immunother"},{"issue":"4","key":"4475_CR16","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ymthe.2018.02.001","volume":"26","author":"KCMJ Pituch","year":"2018","unstructured":"Pituch KCMJ, Krenciute G, Panek WK, Li G, Rodriguez-Cruz T, Wu M, Han Y, Lesniak MS, Gottschalk S, Balyasnikova IV (2018) Adoptive transfer of IL13R\u03b12-specific chimeric antigen receptor T cells creates a pro-inflammatory environment in glioblastoma. Mol Ther 26(4):986\u2013995","journal-title":"Mol Ther"},{"issue":"1","key":"4475_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20599-x","volume":"12","author":"GLA Agliardi","year":"2021","unstructured":"Agliardi GLA, Hotblack A, De Feo D, N\u00fa\u00f1ez N, Stowe CL, Friebel E, Nannini F, Rindlisbacher L, Roberts TA, Ramasawmy R, Williams IP, Siow BM, Lythgoe MF, Kalber TL, Quezada SA, Pule MA, Tugues S, Straathof K, Becher B (2021) Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun 12(1):444","journal-title":"Nat Commun"},{"issue":"1","key":"4475_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1757360","volume":"9","author":"SHS Murty","year":"2020","unstructured":"Murty SHS, Beinat C, Aalipour A, Alam IS, Murty T, Shaffer TM, Patel CB, Graves EE, Mackall CL, Gambhir SS (2020) Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model. Oncoimmunology 9(1):1757360","journal-title":"Oncoimmunology"},{"issue":"1","key":"4475_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","volume":"31","author":"GZZ Wang","year":"2023","unstructured":"Wang GZZ, Zhong K, Wang Z, Yang N, Tang X, Li H, Lu Q, Wu Z, Yuan B, Zheng M, Cheng P, Tong A, Zhou L (2023) CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther 31(1):134\u2013153","journal-title":"Mol Ther"},{"issue":"2","key":"4475_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/neuonc\/noab182","volume":"24","author":"PHY Chuntova","year":"2022","unstructured":"Chuntova PHY, Naka R, Yamamichi A, Chen T, Goretsky Y, Hatae R, Nejo T, Kohanbash G, Mende AL, Montoya M, Downey KM, Diebold D, Skinner J, Liang HE, Schwer B, Okada H (2022) Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice. Neuro Oncol 24(2):259\u2013272","journal-title":"Neuro Oncol"},{"issue":"1","key":"4475_CR21","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1038\/s41467-021-23817-2","volume":"12","author":"LMI Rousso-Noori","year":"2021","unstructured":"Rousso-Noori LMI, Talmor S, Waks T, Globerson Levin A, Haugas M, Teesalu T, Alvarez-Vallina L, Eshhar Z, Friedmann-Morvinski D (2021) P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas. Nat Commun 12(1):3615","journal-title":"Nat Commun"},{"issue":"4","key":"4475_CR22","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","volume":"78","author":"TWM Weiss","year":"2018","unstructured":"Weiss TWM, Guckenberger M, Sentman CL, Roth P (2018) NKG2D-Based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res 78(4):1031\u20131043","journal-title":"Cancer Res"},{"issue":"2","key":"4475_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006239","volume":"11","author":"MDJ Zannikou","year":"2023","unstructured":"Zannikou MDJ, Levine RN, Seblani M, Liu Q, Presser A, Arrieta VA, Chen CJ, Sonabend AM, Horbinski CM, Lee-Chang C, Miska J, Lesniak MS, Gottschalk S, Balyasnikova IV (2023) IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. J Immunother Cancer 11(2):e006239","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4475_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza NA, Wilson AL, Huang W, Seidel K, Brown C, Gustafson JA et al (2023) Intraventricular B7\u2013H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov 13(1):114\u2013131","journal-title":"Cancer Discov"},{"issue":"3","key":"4475_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/85339","volume":"2","author":"AI Chapoval","year":"2001","unstructured":"Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D et al (2001) B7\u2013H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2(3):269\u2013274","journal-title":"Nat Immunol"},{"issue":"1","key":"4475_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","volume":"22","author":"AA Getu","year":"2023","unstructured":"Getu AA, Tigabu A, Zhou M, Lu J, Fodstad \u00d8, Tan M (2023) New frontiers in immune checkpoint B7\u2013H3 (CD276) research and drug development. Mol Cancer 22(1):43","journal-title":"Mol Cancer"},{"issue":"14","key":"4475_CR27","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","volume":"18","author":"D Loo","year":"2012","unstructured":"Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S et al (2012) Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res 18(14):3834\u20133845","journal-title":"Clin Cancer Res"},{"issue":"21","key":"4475_CR28","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.1158\/1078-0432.CCR-21-4384","volume":"28","author":"HLT Meister","year":"2022","unstructured":"Meister HLT, Roth P, Pascolo S, Sahin U, Lee S, Hale BD, Snijder B, Regli L, Ravi VM, Heiland DH, Sentman CL, Weller M, Weiss T (2022) Multifunctional mRNA-Based CAR T cells display promising antitumor activity against glioblastoma. Clin Cancer Res 28(21):4747\u20134756","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4475_CR29","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"LTH Jin","year":"2019","unstructured":"Jin LTH, Karachi A, Long Y, Hou AY, Na M, Dyson KA, Grippin AJ, Deleyrolle LP, Zhang W, Rajon DA, Wang QJ, Yang JC, Kresak JL, Sayour EJ, Rahman M, Bova FJ, Lin Z, Mitchell DA, Huang J (2019) CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun 10(1):4016","journal-title":"Nat Commun"},{"issue":"14","key":"4475_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1085547","volume":"3","author":"SLMN Swan","year":"2023","unstructured":"Swan SLMN, Ilich E, Shen SH, Wilkinson DS, Anderson AR, Segura T, Sanchez-Perez L, Sampson JH, Bellamkonda RV (2023) IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma. Front Immunol 3(14):1085547","journal-title":"Front Immunol"},{"key":"4475_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","author":"JHWP Choe","year":"2021","unstructured":"Choe JHWP, Simic MS et al (2021) SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abe7378","journal-title":"Sci Transl Med"},{"issue":"7786","key":"4475_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RCWE Lynn","year":"2019","unstructured":"Lynn RCWE, Sotillo E, Gennert D, Xu P, Good Z, Anbunathan H, Lattin J, Jones R, Tieu V, Nagaraja S, Granja J, de Bourcy CFA, Majzner R, Satpathy AT, Quake SR, Monje M, Chang HY, Mackall CL (2019) c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576(7786):293\u2013300","journal-title":"Nature"},{"issue":"6","key":"4475_CR33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AHHW Long","year":"2015","unstructured":"Long AHHW, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL (2015) 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21(6):581\u2013590","journal-title":"Nat Med"},{"key":"4475_CR34","doi-asserted-by":"crossref","unstructured":"Zhang P ZY, Ji N. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions. Front Immunol. 2022 2022; Jul 7(13): 927132.","DOI":"10.3389\/fimmu.2022.927132"},{"issue":"8","key":"4475_CR35","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"LMA Cherkassky","year":"2016","unstructured":"Cherkassky LMA, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 126(8):3130\u20133144","journal-title":"J Clin Invest"},{"issue":"2","key":"4475_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/neuonc\/noab182","volume":"24","author":"P Chuntova","year":"2022","unstructured":"Chuntova P, Hou Y, Naka R, Yamamichi A, Chen T, Goretsky Y et al (2022) Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice. Neuro Oncol 24(2):259\u2013272","journal-title":"Neuro Oncol"},{"issue":"4","key":"4475_CR37","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/1078-0432.CCR-13-0709","volume":"20","author":"JH Sampson","year":"2014","unstructured":"Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT et al (2014) EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 20(4):972\u2013984","journal-title":"Clin Cancer Res"},{"key":"4475_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010083","author":"T Inthanachai","year":"2025","unstructured":"Inthanachai T, Boonkrai C, Phakham T, Pisitkun T, Thaiwong R, Chuthaphakdikun V et al (2025) Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-010083","journal-title":"J Immunother Cancer"},{"key":"4475_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009486","author":"L Lertsumitkul","year":"2024","unstructured":"Lertsumitkul L, Iliopoulos M, Wang SS, McArthur SJ, Ebert LM, Davenport AJ et al (2024) EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-009486","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04475-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04475-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04475-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:06:52Z","timestamp":1791252412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04475-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4475"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04475-z","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee of The University of Osaka Graduate School of Medicine (approval numbers: 03\u2013071-000 and 04\u2013028-002) and were performed following the animal use guidelines of the Animal Experiment Committee of The University of Osaka Graduate School of Medicine.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee of The University of Osaka Graduate School of Medicine (approval numbers: 03\u2013071-000 and 04\u2013028-002) and were performed following the animal use guidelines of the Animal Experiment Committee of The University of Osaka Graduate School of Medicine.","order":6,"name":"Ethics","label":"Research involving human participants and\/or animals","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"243"}}